2023-504523-83-00CompletedPhase 4
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects.
Laboratorios Leon Farma S.A.1 site in 1 country45 target enrollmentStarted: June 7, 2023Last updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Laboratorios Leon Farma S.A.
- Enrollment
- 45
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Amparo Amilburu
Scientific
Laboratorios Leon Farma S.A.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects.2023-504527-40-00Laboratorios Leon Farma S.A.80
Recruiting
Phase 4
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.2025-520736-41-00Laboratorios Leon Farma S.A.45
Not yet recruiting
Phase 4
Comparison of The Effect of Implant and injectable contraceptive on Menstrual PatterCTRI/2024/07/071211isha R
Withdrawn
Phase 4
Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)HIV-1-infectionNCT05156658Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Completed
Phase 3
Effect of transdermal Estradiol gel compare Estradiol valerat on endometrial preparation in freeze embryo transfer cycle cycleCondition 1: freeze transfer embryo. Condition 2: preparation of Endometrium for freeze embryo transfer.Disease of the genitourinary systemIRCT2016092429951N1Vice Chancellor for Research, Tehran University of Medical Sciences100